Vygenerované: 29.10.2026 15:25:56
Súhrn: The early termination of a clinical test of immunotherapy de-escalation in patients with a variety of advanced or metastatic cancers may hold important lessons for the field, researchers said The MOIO trial was halted in May following a significant and unexpected increase in deaths among patients receiving less-frequent dosing of immune checkpoint inhibitor (ICI) therapy, according to a presentation at the European Society for Medical Oncology (ESMO) Annual Meeting 2026 in Madrid, Spain At the first interim analysis, there were nearly twice as many deaths among patients receiving less-frequent ICI therapy compared with those receiving standard-frequency dosing: 19.
Doplnenie: However, a subgroup analysis — while only hypothesis-generating — suggested that the effects of ICI de-intensification might not be uniform across patients with different cancer types.
Súhrn: According to a World Health Organization (WHO) survey, only 15% of people in the EU know that alcohol increases the risk for breast cancer To address this gap, WHO/Europe launched a new digital hub called the Alcohol Screening and Brief Interventions Hub with a built-in AI assistant during Breast Cancer Awareness Month that provides health professionals with the tools they need to talk about alcohol and cancer risk The hub features an AI assistant designed to help healthcare professionals and other stakeholders identify and address alcohol-related risks.
Doplnenie: The hub features an AI assistant designed to help healthcare professionals and other stakeholders identify and address alcohol-related risks.
Súhrn: First personalised cancer vaccine cuts risk of disease returning in major trial - Published A new personalised cancer vaccine given alongside a widely used immunotherapy drug has cut the risk of patients dying or their skin cancer returning by 42% in a major clinical trial The researchers involved say the results could mark a turning point in cancer treatment, bringing personalised medicine a step closer The trial also found that the new drug combination reduced the risk of melanoma, a type of skin cancer, spreading by 38% over two years compared to immunotherapy alone.
Doplnenie: The drug manufacturers MSD and Moderna say the same approach is already being tested against other tumours, including kidney, bladder and lung cancer.
Súhrn: GP says she was forced out of job after raising concerns about gender treatment - Published A doctor who raised concerns about the treatment of children questioning their gender has told the BBC she was accused of transphobia, bullied and harassed out of her child protection job in the NHS She has brought a claim of constructive dismissal against the NHS Sussex Integrated Care Board (ICB), which managed health services in the county, and Adam Doyle, who was the ICB's chief executive until 2025 Unacceptable waits for adult gender clinic appointments, review says - Published18 December 2025 "I was just bewildered really that the medical and safeguarding issues were completely lost," she said.
Doplnenie: She has brought a claim of constructive dismissal against the NHS Sussex Integrated Care Board (ICB), which managed health services in the county, and Adam Doyle, who was the ICB's chief executive until 2025.